Filing Flows › United Therapeutics (UTHR) › Guidance & outlook

United Therapeutics (UTHR) guidance and outlook

United Therapeutics' 10-Q filed Nov 4, 2026 makes 39 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 4, 2026

• • Expectations of revenues, expenses, profitability, cash flows, and growth in the number of patients being treated with our products, including continued growth in sales of Tyvaso DPI, and anticipated growth in the number of patients with pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) being treated with our Tyvaso products;
• • The expected volume and timing of sales of our commercial products, as well as potential future commercial products, including the anticipated effect of various sales, marketing, research and developm ent efforts on sales of these products;
• • The expectation that we will be able to manufacture sufficient quantities and maintain adequate inventories of our commercial products, through both our in-house manufacturing capabilities and third-party manufacturing sites;
• In September 2025, we launched a new version of the Remunity Pump, called RemunityPRO, which is intended to improve the patient experience by making the pump easier to use.
• We have no plans to enter into an amendment to extend the term of the license, and our rights to commercialize Adcirca will terminate upon its expiration.
• Competition from these generic companies could reduce our net product sales and profits.
• We believe this outcome will result in an increase in the number of patients being prescribed Nebulized Tyvaso and Tyvaso DPI for PH-ILD, although the timing and extent of this impact is uncertain as it is unclear to what extent Yutrepia will continue to be used off-label to treat PH-ILD.
• We intend to vigorously enforce our intellectual property rights related to our products.
• Our cost of sales primarily includes costs to manufacture our products, royalty and sales-based milestone payments under license agreements granting us rights to sell related products, direct and indirect distribution costs incurred in the sale of our products, and the costs of inventory reserves for current and projected obsolescence.
• ( Arena ) on November 3, 2026 in connection with an amendment to our licensing agreement with Arena (the Arena Amendment ), discussed below, which we expect to record during the fourth quarter of 2026), and adjustments to the fair value of our contingent consideration obligations.
• We expect topline data from the TETON-PPF study will be available in the second half of 2027.
• We and our distributors will also consider seeking amendments to the marketing authorizations for Nebulized Tyvaso in other countries where it is approved, to include IPF and/or PPF indications, and we will also consider seeking approval of Nebulized Tyvaso for these indications in countries where it is not yet approved.

United Therapeutics' latest quarter

Questions

What does United Therapeutics expect?

• Expectations of revenues, expenses, profitability, cash flows, and growth in the number of patients being treated with our products, including continued growth in sales of Tyvaso DPI, and anticipated growth in the number of patients with pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) being treated with our Tyvaso products; • The expected volume and timing of sales of our commercial products, as well as potential future commercial products, including the anticipated effect of various sales, marketing, research and developm ent efforts on sales of these products; •

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.